Metsera (NASDAQ:MTSR) Stock Price Up 7.6% – Still a Buy?

Metsera, Inc. (NASDAQ:MTSR)’s share price rose 7.6% during mid-day trading on Monday . The company traded as high as $28.28 and last traded at $27.12. Approximately 40,441 shares changed hands during trading, a decline of 93% from the average daily volume of 557,944 shares. The stock had previously closed at $25.21.

Analysts Set New Price Targets

Several equities research analysts have recently commented on MTSR shares. Cantor Fitzgerald began coverage on Metsera in a report on Tuesday, February 25th. They issued an “overweight” rating for the company. Bank of America assumed coverage on shares of Metsera in a research report on Tuesday, February 25th. They set a “buy” rating and a $38.00 price target on the stock. Guggenheim began coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued a “buy” rating and a $56.00 price objective for the company. Finally, Evercore ISI assumed coverage on shares of Metsera in a report on Tuesday, February 25th. They issued an “outperform” rating on the stock.

Metsera Trading Up 11.7 %

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.